371 related articles for article (PubMed ID: 12230441)
1. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies.
Bindra R; Heath V; Liao A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2002 Sep; 20(3):219-25. PubMed ID: 12230441
[TBL] [Abstract][Full Text] [Related]
2. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
3. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nicolaides KH; Spencer K; Avgidou K; Faiola S; Falcon O
Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
[TBL] [Abstract][Full Text] [Related]
4. Prospective validation of first-trimester combined screening for trisomy 21.
Kagan KO; Etchegaray A; Zhou Y; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2009 Jul; 34(1):14-8. PubMed ID: 19526452
[TBL] [Abstract][Full Text] [Related]
5. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
Soergel P; Pruggmayer M; Schwerdtfeger R; Muhlhaus K; Scharf A
Fetal Diagn Ther; 2006; 21(3):264-8. PubMed ID: 16601335
[TBL] [Abstract][Full Text] [Related]
6. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
[TBL] [Abstract][Full Text] [Related]
7. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
Spencer K; Cowans NJ; Avgidou K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Oct; 28(5):637-43. PubMed ID: 16952214
[TBL] [Abstract][Full Text] [Related]
8. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Valencia C; Maiz N; Nicolaides KH
Hum Reprod; 2008 Sep; 23(9):1968-75. PubMed ID: 18544579
[TBL] [Abstract][Full Text] [Related]
9. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
Spencer K; Bindra R; Cacho AM; Nicolaides KH
Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947
[TBL] [Abstract][Full Text] [Related]
10. First trimester predictors of adverse pregnancy outcomes.
Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
[TBL] [Abstract][Full Text] [Related]
11. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
[TBL] [Abstract][Full Text] [Related]
12. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
[TBL] [Abstract][Full Text] [Related]
13. Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21.
Nicolaides KH; Chervenak FA; McCullough LB; Avgidou K; Papageorghiou A
Am J Obstet Gynecol; 2005 Aug; 193(2):322-6. PubMed ID: 16098850
[TBL] [Abstract][Full Text] [Related]
14. Comparing first trimester screening performance: routine care gynaecologists' practices vs. prenatal centre.
Kozlowski P; Knippel AJ; Stressig R
Ultraschall Med; 2007 Jun; 28(3):291-5. PubMed ID: 17315110
[TBL] [Abstract][Full Text] [Related]
15. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
[TBL] [Abstract][Full Text] [Related]
16. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
[TBL] [Abstract][Full Text] [Related]
17. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
[TBL] [Abstract][Full Text] [Related]
18. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery.
Spencer K; Cowans NJ; Molina F; Kagan KO; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Feb; 31(2):147-52. PubMed ID: 17992705
[TBL] [Abstract][Full Text] [Related]
19. Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
Kagan KO; Anderson JM; Anwandter G; Neksasova K; Nicolaides KH
Prenat Diagn; 2008 Dec; 28(13):1209-13. PubMed ID: 19039823
[TBL] [Abstract][Full Text] [Related]
20. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
